|Bid||56.25 x 100|
|Ask||56.50 x 1000|
|Day's Range||56.41 - 56.94|
|52 Week Range||46.01 - 60.45|
|PE Ratio (TTM)||19.60|
|Dividend & Yield||1.56 (2.76%)|
|1y Target Est||N/A|
In June 2017, Bristol-Myers Squibb presented the clinical trial data of its Phase 1/2 ECHO-204 trial.
In 2Q17, Bristol-Myers Squibb’s (BMY) Opdivo generated revenues of around $1.2 billion, which reflected ~45% growth on a year-over-year basis.
In 2Q17, Bristol-Myers Squibb reported diluted earnings per share (or EPS) of $0.56 compared to $0.69 in 2Q16.